A US advisory panel on Tuesday backed MedImmune Inc.’s nasal spray influenza vaccine FluMist. The FDA advisory panel voted that FluMist was safe and effective for healthy people aged 5 to 49.
For people aged 50 to 64, the panel voted that FluMist was safe but the majority of panel members said there was not enough data to prove FluMist was effective for people in that age group.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!